By studying the roles two proteins, thrombospondin-1 and prosaposin, play in discouraging cancer metastasis, a trans-Atlantic research team has identified a five-amino acid fragment of prosaposin that significantly reduces metastatic spread in mouse models of prostate, breast and lung cancer.
[More]
Ambulatory pumps allow patients to continue receiving treatment or therapy away from a hospital, thereby leading a normal life during treatment. Due to the size and design of these pumps, patients can carry them around in a carry pouch.
[More]
A new analysis has provided a comprehensive comparison of scores designed to predict which women with oestrogen-receptor positive breast cancer are at high risk of recurrence beyond five years after diagnosis, and may benefit from prolonged endocrine treatment.
[More]
The study Dr. Chlebowski authored reported that estrogen plus progestin use is linked with increased breast cancer incidence. In addition, it said the prognosis is similar for both users and nonusers of combined hormone therapy, suggesting that mortality from breast cancer may be higher for hormone therapy users as well.
[More]
Post-menopausal women, who often suffer from joint pain, could find some long-term relief by taking estrogen-only medication, according to a new study based on the Women's Health Initiative (WHI) that was released online today by the journal, Menopause.
[More]
Low-grade serous ovarian cancer is less common and aggressive than the high-grade variety, yet exceptionally difficult to treat when frontline therapy fails.
[More]
Prostate cancer experts at Johns Hopkins have developed an updated version of the Partin Tables, a tool to help men diagnosed with prostate cancer and their doctors to better assess their chance of a surgical cure. The updated tool, based on a study of more than 5,600 men treated at The Johns Hopkins Hospital from 2006 to 2011, is published in the Jan. 3 issue of the British Journal of Urology International.
[More]
Prostate cancer experts at Johns Hopkins have developed an updated version of the Partin Tables, a tool to help men diagnosed with prostate cancer and their doctors to better assess their chance of a surgical cure. The updated tool, based on a study of more than 5,600 men treated at The Johns Hopkins Hospital from 2006 to 2011, is published in the Jan. 3 issue of the British Journal of Urology International.
[More]
Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced it is initiating development of its lead cancer drug BP-100-1.01 (Liposomal Grb-2) to treat triple negative breast cancer (TNBC) and inflammatory breast cancer (IBC), two cancers characterized by formation of aggressive tumors and relatively high mortality rates.
[More]
A study led by a Michigan State University researcher offers the strongest evidence yet that reflexology - a type of specialized foot massage practiced since the age of pharaohs - can help cancer patients manage their symptoms and perform daily tasks.
[More]
Scientists have identified a molecular 'flag' in women with breast cancer who do not respond or have become resistant to the hormone drug tamoxifen.
[More]
Elderly women with early-stage breast cancer live longer with radiation therapy and surgery compared with surgery alone, researchers at the University of Maryland School of Medicine have found.
[More]
AstraZeneca today announced the start of a Phase III study (FALCON), a global clinical trial which will involve 450 postmenopausal patients with hormone receptor-positive locally advanced or metastatic breast cancer who have not previously been treated with any hormonal therapy. The Phase III study is designed to evaluate the efficacy and tolerability of fulvestrant 500 mg compared to anastrozole 1 mg in this patient population.
[More]
Ductal carcinoma in situ (DCIS) is considered a precursor lesion for invasive breast cancer if untreated, and is found in approximately 45% of patients with invasive ductal carcinoma (IDC). Patients with DCIS only (not accompanied by invasive disease) have a 5-year-survival of nearly 100%, compared to 89% for all stages of invasive breast cancer (24% for patients with distant metastasis).
[More]
ProStrakan Group plc announces today that it has acquired exclusive US commercial rights to Fareston (toremifene citrate) for the treatment of metastatic breast cancer in postmenopausal women.
[More]
Four new studies on the treatment of early breast cancer, spanning from diagnosis through surgery, were released today in advance of the 2012 Breast Cancer Symposium.
[More]
GenSpera, Inc. announced that the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom (UK) has cleared for initiation a Phase II human clinical trial of its lead compound, G-202, in the treatment of prostate cancer patients who have failed prior hormonal therapy.
[More]
Extra pounds-even within the overweight but not obese range-are linked to a higher risk of recurrence of the most common type of breast cancer despite optimal cancer treatment, according to a new study published early online in CANCER, a peer-reviewed journal of the American Cancer Society.
[More]
GTx, Inc. today provided a Company update and reported financial results for the second quarter of 2012.
[More]
A study co-authored by a Loyola researcher and published in the New England Journal of Medicine is offering new hope to women with advanced breast cancer.
[More]